Department of Reproductive Medicine, The Second Hospital, Hebei Medical University, 215 West Heping Road, Shijiazhuang, 050000, Hebei Province, People's Republic of China.
Department of Interventional Therapy, Henan Provincial People's Hospital, 7 Weiwu Road, Zhengzhou, 450003, Hebei Province, People's Republic of China.
J Endocrinol Invest. 2019 Jan;42(1):27-35. doi: 10.1007/s40618-018-0877-1. Epub 2018 Apr 18.
To investigate whether growth hormone (GH) could improve pregnancy rates of patients with thin endometrium by clinical study and laboratory experiments.
Ninety-three patients were randomized to either the GH-received group (40) or the routine exogenous administration of estrogens control group (53) for clinical study. The human endometrial carcinoma cell line RL95-2 was used for testing the role of GH with Western blot and real-time PCR by exposure to various concentrations of GH (0.1 nM,1 nM,10 nM,100 nM).
Patients treated with GH had a significantly (P < 0.05) greater endometrium thickness on day 3 (7.87±0.72 vs 6.34±0.86), higher implantation rates (24.4% vs 10.5%) and greater clinical pregnancy rates (42.5% vs 18.9%) compared with the control group. No adverse events were associated with the use of GH. Administration of GH significantly up-regulated the expression of VEGF, ItgB3 and IGF-I expression in RL95-2 cells at both mRNA and protein levels (P < 0.05). AG490, an inhibitor of JAK2, nearly completely inhibited the up-regulative effect of GH through the JAK2-STAT5 pathway, and GH-induced effects could be mediated through autocrine IGF-I together with its hepatic counterpart. IGF-I mRNA was detected in the RL95-2 cells.
GH may improve pregnancy outcomes of patients with thin endometrium who undergo frozen embryo transfer by acting on human endometrial cells to promote proliferation and vascularization and to up-regulate receptivity-related molecular expression.
通过临床研究和实验室实验，探讨生长激素（GH）是否可以提高薄型子宫内膜患者的妊娠率。
93 例患者随机分为 GH 组（40 例）和常规外源性雌激素对照组（53 例）进行临床研究。采用 Western blot 和实时 PCR 法检测不同浓度 GH（0.1 nM、1 nM、10 nM、100 nM）对人子宫内膜癌细胞系 RL95-2 的作用。
GH 组患者第 3 天子宫内膜厚度显著增加（7.87±0.72 比 6.34±0.86，P<0.05），着床率（24.4%比 10.5%）和临床妊娠率（42.5%比 18.9%）均显著高于对照组（P<0.05）。GH 治疗无不良反应。GH 可显著上调 RL95-2 细胞中 VEGF、ItgB3 和 IGF-I 的表达（mRNA 和蛋白水平均 P<0.05）。JAK2 抑制剂 AG490 通过 JAK2-STAT5 通路几乎完全抑制 GH 的上调作用，而 GH 诱导的作用可通过自分泌 IGF-I 及其肝对应物介导。RL95-2 细胞中检测到 IGF-I mRNA。
GH 通过作用于人子宫内膜细胞促进增殖和血管生成，上调容受性相关分子的表达，可能改善接受冻融胚胎移植的薄型子宫内膜患者的妊娠结局。
